This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Zumutor Biologics Inc.
Pfizer
Taiho Oncology, Inc.
OncoNano Medicine, Inc.
Compass Therapeutics
Immunitas Therapeutics
Nurix Therapeutics, Inc.
ModernaTX, Inc.
Shattuck Labs, Inc.
GlaxoSmithKline
Seagen Inc.
RAPT Therapeutics, Inc.
Cyteir Therapeutics, Inc.
Zhejiang Provincial People's Hospital
Presage Biosciences
Eisai Inc.
Icahn School of Medicine at Mount Sinai
Corvus Pharmaceuticals, Inc.
Rutgers, The State University of New Jersey
Sierra Oncology LLC - a GSK company
Eastern Cooperative Oncology Group
Seagen Inc.
Genzada Pharmaceuticals USA, Inc.
Ludwig Institute for Cancer Research
Presage Biosciences
Celgene
University College, London
Institut Bergonié
Incyte Corporation
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Peking University
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center